Belantamab Mafodotin-Blmf

The combination of belantamab mafodotin, pomalidomide and dexamethasone extended PFS compared with standard care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.

GSK has started the process of withdrawing belantamab mafodotin-blmf from the U.S. market.

Belantamab mafodotin-blmf failed to extend PFS compared with pomalidomide and dexamethasone for adults with relapsed or refractory multiple myeloma, according to topline data from a confirmatory trial released by the agent’s manufacturer.

Novel therapies and treatment strategies could help to address the clinical challenges of triple-class refractory multiple myeloma, according to a speaker at Chemotherapy Foundation Symposium.

An independent panel unanimously agreed that chimeric antigen receptor T-cell therapy provides clinical benefit superior to the current standard of care for patients with relapsed or refractory multiple myeloma.

Chimeric antigen receptor T-cell therapies demonstrated greater clinical effectiveness than standard care among patients with heavily pretreated multiple myeloma, according to a report by the Institute for Clinical and Economic Review.

The Institute for Clinical and Economic Review published a draft evidence report assessing the comparative clinical effectiveness and value of B-cell maturation antigen-directed therapies for heavily pretreated multiple myeloma.

The Institute for Clinical and Economic Review has completed a draft scoping document for its planned assessment of chimeric antigen receptor T-cell therapies for the treatment of multiple myeloma.

The FDA granted accelerated approval to belantamab mafodotin-blmf for treatment of relapsed or refractory multiple myeloma.

The FDA has made several notable approvals and decisions on treatment for multiple myeloma in the past year. To highlight new and emerging therapies, Healio compiled a list of these potentially practice-changing FDA actions.